Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1211-1220 of 1,467) with videos related to

Pageof 147
Sort By:
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|January 7, 2006
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)B Combe, R Landewe, C Lukas, et al.
Cytokine|October 1, 2021
Ontogeny of plasma cytokine and chemokine concentrations across the first week of human lifeKinga K Smolen, Alec L Plotkin, Casey P Shannon, et al.
Annals of the Rheumatic Diseases|March 17, 2017
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritisSofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, et al.
Rheumatology and Therapy|November 17, 2020
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H StudyJosef S Smolen, Anthony Sebba, Eric M Ruderman, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Clinical and Experimental Rheumatology|October 21, 1998
Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLEM Galeazzi, G Morozzi, G D Sebastiani, et al.
The New England Journal of Medicine|November 30, 2000
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupP E Lipsky, D M van der Heijde, E W St Clair, et al.
Annals of the Rheumatic Diseases|March 13, 2010
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritisKlaus P Machold, Robert Landewé, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue diseaseJörg H W Distler, Tobias Strapatsas, Dörte Huscher, et al.
Pageof 147

Showing results (1211-1220 of 1,467) with videos related to

Sort By:
Pageof 147
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|January 7, 2006
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)B Combe, R Landewe, C Lukas, et al.
Cytokine|October 1, 2021
Ontogeny of plasma cytokine and chemokine concentrations across the first week of human lifeKinga K Smolen, Alec L Plotkin, Casey P Shannon, et al.
Annals of the Rheumatic Diseases|March 17, 2017
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritisSofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, et al.
Rheumatology and Therapy|November 17, 2020
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H StudyJosef S Smolen, Anthony Sebba, Eric M Ruderman, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Clinical and Experimental Rheumatology|October 21, 1998
Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLEM Galeazzi, G Morozzi, G D Sebastiani, et al.
The New England Journal of Medicine|November 30, 2000
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupP E Lipsky, D M van der Heijde, E W St Clair, et al.
Annals of the Rheumatic Diseases|March 13, 2010
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritisKlaus P Machold, Robert Landewé, Josef S Smolen, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue diseaseJörg H W Distler, Tobias Strapatsas, Dörte Huscher, et al.
Pageof 147